The antiphospholipid syndrome (APS) is defined by the development of venous and/or
arterial thromboses, often multiple, and pregnancy morbidity (mainly, recurrent fetal losses),
in the presence of antiphospholipid antibodies (aPL). Some estimates indicate that the
incidence of the APS is around 5 new cases per 100,000 persons per year and the
prevalence around 40–50 cases per 100,000 persons. The aPL are positive in
approximately 13% of patients with stroke, 11% with myocardial infarction, 9.5% of patients …